A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
Clinical trial NCT03875482 · COMPLETED
Trial details
- NCT number
- NCT03875482
- Sponsor
- AbbVie
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-13
- Primary completion
- 2020-02-20
- Enrollment
- 157
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.